Search

Your search keyword '"SHELLEY ZIEROTH"' showing total 168 results

Search Constraints

Start Over You searched for: Author "SHELLEY ZIEROTH" Remove constraint Author: "SHELLEY ZIEROTH"
168 results on '"SHELLEY ZIEROTH"'

Search Results

1. The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis

2. Heart Failure Management in 2023: A Pharmacotherapy- and Lifestyle-Focused Comparison of Current International Guidelines

Catalog

Books, media, physical & digital resources

3. Prevalence, characteristics and mortality of cancer patients undergoing pericardiocentesis in the United States between 2004 and 2017

4. The State of Heart Failure Care in Canada: Minimal Improvement in Readmissions Over Time Despite an Increased Number of Evidence-Based Therapies

5. Polymorphic Ventricular Tachycardia Detected With a SmartwatchNovel Teaching Points

6. Characteristics of Clinicians Are Associated With Their Beliefs About ICD Deactivation: Insight From the DECIDE-HF Study

7. Sex, Gender, and Equity in Cardiovascular Medicine, Surgery, and Science in Canada: Challenges, Successes, and Opportunities for Change

8. Optimal Usage of Sacubitril/Valsartan for the Treatment of Heart Failure: The Importance of Optimizing Heart Failure Care in Canada

9. COVID-19 Pandemic: Global Impact and Potential Implications for Cardiovascular Disease in Canada

10. The Status of Specialized Ambulatory Heart Failure Care in Canada: A Joint Canadian Heart Failure Society and Canadian Cardiovascular Society Heart Failure Guidelines Survey

11. Gender Differences in International Cardiology Guideline Authorship: A Comparison of the US, Canadian, and European Cardiology Guidelines From 2006 to 2020

12. National Trends of Gender Disparity in Canadian Cardiovascular Society Guideline Authors, 2001-2020

13. Comparative effectiveness of the different components of care provided in heart failure clinics—protocol for a systematic review and network meta-analysis

14. Hyperkalaemia in Heart Failure

15. A Comprehensive Analysis of the Efficacy of Resveratrol in Atherosclerotic Cardiovascular Disease, Myocardial Infarction and Heart Failure

16. Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats

18. Sex Differences in Characteristics, Outcomes, and Treatment Response with Dapagliflozin Across the Range of Ejection Fraction in Patients with Heart Failure

19. Participating in the Peer Review Process: The Journal of Cardiac Failure Construct

21. Dapagliflozin in heart failure with improved ejection fraction

22. Current status of perioperative temporary mechanical circulatory support during cardiac surgery

23. The impact of the COVID-19 pandemic on heart failure management: Global experience of the OPTIMIZE Heart Failure Care network

24. 2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults

26. Patient Phenotype Profiling in Heart Failure with Preserved Ejection Fraction to Guide Therapeutic Decision Making A Scientific Statement of the Heart Failure Association (HFA) and the European Heart Rhythm Association (EHRA) of the ESC, and the European Society of Hypertension (ESH)

27. Guardians For Health: A Practical Approach to Improving Quality of Life and Longevity in People with Type 2 Diabetes

28. Canadian Cardiovascular Society – Canadian Heart Failure Society Focused Clinical Practice Update of Patients with Differing Heart Failure Phenotypes

32. Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial

33. Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial

34. Time for change

35. Reflecting on the advancements of HFrEF therapies over the last two decades and predicting what is yet to come

36. Characteristics of Clinicians Are Associated With Their Beliefs About ICD Deactivation: Insight From the DECIDE-HF Study

37. National Trends of Gender Disparity in Canadian Cardiovascular Society Guideline Authors, 2001-2020

38. An international Delphi consensus regarding best practice recommendations for hyperkalaemia across the cardiorenal spectrum

39. Are Post Hoc Analyses on Subgroups Sufficient to Support New Treatment Algorithms of Heart Failure? The Case of SGLT2 Inhibitors Associated with Sacubitril/Valsartan

40. Sex, Gender, and Equity in Cardiovascular Medicine, Surgery, and Science in Canada: Challenges, Successes, and Opportunities for Change

41. Optimal Usage of Sacubitril/Valsartan for the Treatment of Heart Failure: The Importance of Optimizing Heart Failure Care in Canada

42. Cardiac Rehabilitation During the COVID-19 Era: Guidance on Implementing Virtual Care

43. Guiding Cardiac Care During the COVID-19 Pandemic: How Ethics Shapes Our Health System Response

44. Managing Common Co-morbidities in Heart Failure

45. Hyperkalemia in heart failure

46. Canadian Cardiovascular Society/Canadian Cardiac Transplant Network Position Statement on Heart Transplantation: Patient Eligibility, Selection, and Post-Transplantation Care

47. CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis

48. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

49. Aiming at harmony. Comparing and contrasting International HFrEF Guidelines